Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Resistance and Management of Treatment-Experienced Patients

Faculty:

W. David Hardy, MD
Kathleen E. Squires, MD
Andrew R. Zolopa, MD

CME CREDIT INFORMATION

Release Date: 04/18/07

Expiration Date: 04/17/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.3 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of studies investigating the prevalence of transmitted antiretroviral resistance mutations
Recall data detailing the lack of clinically significant cross-resistance between amprenavir and darunavir
Describe the clinical significance of resistance mutations selected during antiretroviral therapy to prevent mother-to-child transmission of HIV
Specify data regarding the detection of low-level resistance mutations in minority viral populations
Summarize recent findings of the association between antiretroviral resistance and mortality

Topics covered include:

Postpartum Impact of Prevention of MTCT Strategies
Transmitted Resistance in Pregnant Women
Resistance in Non-B Subtypes
Ultrasensitive Genotypic Resistance Assays
Transmitted Antiretroviral Resistance
Independent Viral Evolution in Seminal Fluid
Resistance and Lopinavir/Ritonavir Monotherapy
Lack of Amprenavir-Darunavir Cross-Resistance
Correlation Between Resistance and Mortality
Therapeutic Strategies for Treatment-Experienced Patients

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.